These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35994091)

  • 1. Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response.
    Costard-Jäckle A; Schramm R; Fischer B; Rivinius R; Bruno R; Müller B; Zittermann A; Boeken U; Westenfeld R; Knabbe C; Gummert J
    Clin Res Cardiol; 2023 Nov; 112(11):1506-1516. PubMed ID: 35994091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
    J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
    Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
    Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
    Peled Y; Ram E; Lavee J; Segev A; Matezki S; Wieder-Finesod A; Halperin R; Mandelboim M; Indenbaum V; Levy I; Sternik L; Raanani E; Afek A; Kreiss Y; Lustig Y; Rahav G
    J Heart Lung Transplant; 2022 Feb; 41(2):148-157. PubMed ID: 34565682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients.
    Hod T; Ben-David A; Olmer L; Scott N; Ghinea R; Mor E; Levy I; Indenbaum V; Lustig Y; Grossman E; Rahav G
    Transpl Int; 2022; 35():10239. PubMed ID: 35387393
    [No Abstract]   [Full Text] [Related]  

  • 8. Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy.
    López V; Polo C; Schuldt R; Vázquez T; Gutiérrez-Vílchez E; Moliz C; Hernández D
    Transplant Proc; 2022 Nov; 54(9):2454-2456. PubMed ID: 36273957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.
    De Cagna MR; Colucci V; Di Maggio A; Notaristefano N; Cianciotta F; Danza K; Salvatore F; Santoniccolo A; Lanzillotta SG; Perniola MA; Marangi AL; Morrone LFP; Tampoia M
    Clin Exp Nephrol; 2023 May; 27(5):445-453. PubMed ID: 36795176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients.
    Shaul AA; Itzhaki Ben Zadok O; Ben-Avraham B; Yaari V; Barsheshet A; Levi A; Ben Zvi H; Eliakim Raz N; Abed G; Abuhazira M; Abu Akel M; Mats I; Barac YD; Aravot D; Kornowski R; Ben-Gal T
    Eur J Cardiothorac Surg; 2022 Sep; 62(4):. PubMed ID: 35244690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.
    Catry E; Favresse J; Gillot C; Bayart JL; Frérotte D; Dumonceaux M; Evrard P; Mullier F; Douxfils J; Carlier FM; Closset M
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients.
    Natori Y; Martin E; Mattiazzi A; Arosemena L; Ortigosa-Goggins M; Shobana S; Roth D; Kupin WL; Burke GW; Ciancio G; Morsi M; Phancao A; Munagala MR; Butrous H; Manickavel S; Sinha N; Sota K; Pallikkuth S; Bini J; Simkins J; Anjan S; Vianna RM; Guerra G
    Transpl Int; 2023; 36():10938. PubMed ID: 37091963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
    Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
    Front Immunol; 2022; 13():832501. PubMed ID: 35281023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac.
    Erol Ç; Kuloğlu ZE; Kayaaslan B; Esken G; Altunsoy A; Barlas T; Çınar G; Hasanoğlu İ; Oruç E; İncir S; Azap A; Korkmaz G; Turan Gökçe D; Kırımker OE; Coşkun Yenigün E; Ölçücüoğlu E; Ayvazoğlu Soy E; Çetinkünar S; Kurt Azap Ö; Can F; Haberal M
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac Vaccine: A Prospective Cohort Study.
    Medina-Pestana J; Almeida Viana L; Nakamura MR; Lucena EF; Granato CFH; Dreige YC; Amorim LVP; Chow CYZ; Demarchi Foresto R; Roberto Requião-Moura L; Tedesco-Silva H; Cristelli MP
    Transplantation; 2022 Oct; 106(10):2076-2084. PubMed ID: 35939382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.
    Hod T; Ben-David A; Olmer L; Levy I; Ghinea R; Mor E; Lustig Y; Rahav G
    Transplantation; 2021 Nov; 105(11):e234-e243. PubMed ID: 34310101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.